drugset / Trial / NCT06778902
AZA Combined with R-GemOx for Elderly DLBCL Patients
Phase 2
Not yet recruiting
80 enrolled
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of AZA（azacytidine）combined with the R-GemOx (rituximab, gemcitabine and oxaliplatin) regimen as first-line treatment in elderly diffuse large B-cell lymphoma (DLBCL) patients.
Timeline
- Start
- 2025-02-01
- Primary completion
- 2028-01-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacytidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1 g | — |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |